GSKNYSE: GSK

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, fell 2% and 11% in New York overnight.

GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on Immunisation Practises announced all those over the age of 75 should only have a single dose of the treatment.

GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending their use for those under 60 years of age.

A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time CEO Summit, boss Emma Walmsley said that even though only 3 per cent of its business is in Britain, GSK switching its listing was "not a debate for us.

GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug giant's decision to challenge a key US court ruling. The Delaware state court ruling allowed plaintiffs' expert testimony in Zantac trials, contrary to a previous Federal court decision dismissing all multi-district litigation (MDL) cases.

GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer.  Analysts had expected the UK drug giant, along with Pfizer, Sanofi and Boehringer Ingelheim to contest the original ruling.

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.